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Abstract
Background: Monitoring of aggregate, ward-supply data and analysis of the anatomical therapeutic chemical/defined daily dose system, adjusted for 
bed-occupancy, provides a clear picture of antibiotics consumption frequency and time-trends within hospitals and especially intensive care departments. 
Material and methods: For this study we used data of a five-year (2010-2014) period, in therapeutic intensive care department of the Emergency Medicine 
Institute, which show the consumption dynamics of anti-infectives for systemic use of drugs in grams and value indexes.
results: The defined daily doses (DDD) per 1000 occupied-bed days (DDD/OBD) of antibiotics in therapeutic intensive care department decreased from 
1524 in 2010 to 1206 DDD/1000 in 2014 or by 20.87%, however, it is by 11.77% higher than medium consumption of 1052.25 DDD/1000 in intensive care 
units with the same activity in international hospitals. The value of 54948 lei per DDD/1000 OBD in 2010 recorded a decline to 40754 lei or by 25.84% 
in 2014. The cost of one medium DDD from 36.05 lei in 2010 decreased to 33.77 lei or by 6.33% in 2014. The average antibiotics annual institution 
consumption constituting 464.1 DDD/1000 in 2014 was higher by 1.06% comparatively with medium consumption of 459.20 DDD/1000 registered in 
1706 international hospitals, and by 35.31% in comparison with global consumption of 343 defined daily doses per 1000 patient-days.  
conclusions: The decrease of DDD/1000 OBD and their cost took place as a result of efforts for rational use of antibiotics during the evaluated period. 
Great opportunities were found for improving rational utilization of anti-infectives for systemic use.
Key words: antibiotics, defined daily dose, consumption, rational use, hospitals.
Introduction
The main function of the Therapeutic intensive care de-
partment of Emergency Medicine Institute consists in provi-
ding measures to recover patients after anesthesia of surgical, 
neurosurgical, traumatological and other investigations as 
well as from other possible critical conditions of hospitalized 
patients. Often these patients are exposed to multiple inva-
sive procedures and have to administrate a multiple broad 
spectrum of antibiotics. At the same time, the prescriptions 
are often empiric and lead to overuse or misuse of antibio-
tics, unnecessary side effects, growth of pathogenic microbes 
resistance to antibiotics and increasing treatment costs. The 
above mentioned requires surveillance, stringent consumption 
control and suppose rational antibiotic prescription [1, 2, 3, 
4]. Unfortunately, in the Republic of Moldova the information 
about antibiotics prescription, consumption patterns, and cost 
analysis in hospitals with only few scientific publications [5, 
9, 10, 20] is rather limited.
National Scientific-Practical Centre of Emergency Medici-
ne of the Republic of Moldova reorganized in 2014 into Emer-
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gency Medical Institute (EMI), was founded in 1959. Clinical 
Services of EMI include: Orthopedic-Traumatology Clinic for 
150 beds, Surgery Clinic for 140 beds,  Neurosurgery Clinic 
for 80 beds, Neurology Clinic for 70 beds, Maxillo-facial clinic 
for 30 beds, Urology Clinic for 40 beds, Gynecology Clinic for 
30 beds, Microsurgery Clinic for 30 beds, Municipal center for 
hemodialysis with 8 seats and 9 beds, Clinical intensive care 
unit for 30 beds including and Therapeutical intensive care 
department for 12 beds, in total the above services of the EMI 
include 600 beds overall.  In addition to the above mentioned 
services include 5 emergency medical help substations and 4 
out-patient Departments of traumatology and orthopedics [6].
The primary aim of the study was to evaluate institutional 
representative data on antibiotics utilization for five-year 
(2010-2014) period, in accordance with World Health Or-
ganization (WHO) requirements, directed to determine the 
value of Defined Daily Doses per 1000 Occupied-Bed Days 
(DDD/1000). That study was carried out and with the support 
of other two programs that were effectuated in the instituti-
on: analysis program of consumption and stocks of drugs in 
Anatomical Therapeutical Chemical (ATC) and pharmaco-
therapeutic software [7, 8]. Based on obtained data, it aimed 
to make conclusions on the use of anti-infectives for systemic 
use in the Therapeutical intensive care department and to 
propose recommendations for ensuring their optimization.
Material and methods
 For this study we used the data of a five-year (2010-2014) 
period in therapeutic intensive care department of EMI for 12 
beds, which show the dynamics of consumption of anti-infec-
tives for systemic use drugs, as classified by ATC classification 
system of World Health Organization indicated in grams and 
value indexes. Statistical, analytical, mathematical, comparati-
ve, logical and descriptive were used as the methods of study.
Results and discussion
For determining the amount of DDD/1000 data about 
total annual consumption of antibiotics and the statistics data 
concerning the number of treated patients (only patients with 
health insurance and other free treated by the state categories 
of citizens), the number of bed/days (2010 = 2922; 2011 = 
3327; 2012 = 3239; 2013 = 3407; 2014 = 3388) during the 
evaluated period in Therapeutical intensive care department 
were used. All in all, 36 antimicrobial remedies with different 
dosage of administration (both for parenteral and enteral use) 
for hospitalized patients’ treatment in the evaluated period 
were used entral forms – 7 names; parenteral forms – 29 
names and 3 names of both forms, which represent 23 active 
antimicrobial substances.
Parenteral consumption forms rate of antibiotic subgroups 
evaluated in DDD/1000 during 2010-2014 is shown in figure 1.
As can be observed from figure 1 in the evaluated period 
the average consumption annual rate of all antibiotic subgro-
ups records a decline from 1504 in 2010 to 1082 DDD/1000 
in 2014 or by 28.06%. The main consumption of 1378.16 
(974.67+285.42+118.07) or 97.63% from the total in 2010 to 
951.01 DDD/1000 (597.7+97.11+256.20) or 87.89% in 2014 by 
a decrease of 427.15 DDD or 31% during the mentioned years 
was registered for three subgroups: other beta-lactam antibac-
terials (Cefazolinum 3.0, Cefuroximum 3.0, Cefotaximum4.0, 
Ceftazidimum 4.0, Ceftriaxonum 2.0, Cefoperazonum 4.0), 
other antibacterials (Vancomycinum 2.0 and Metronidazolum 
1.5) and beta-lactam antibacterials, penicillins (Ampicilli-
num2.0, Amoxycillinum 2.0, Amoxicillinum + Acidumclavu-
lanicum 3.0, Ticarcillinum + Acidumclavulanicum 15.0). The 
mean consumption of 105.75 (35.25+65.02+5.48) or 7.03% of 
the total in 2010 to 125.74 DDD/1000 (59.33+51.06+15.35) 
or 11.62% from the total in 2014 by an increase of 19.99 
DDD/1000 or 18.90% was recorded in the same period by 
other three subgroups: aminoglycoside antibacterials (Strep-
tomycinum 1.0, Gentamycinum 0.2, Kanamycinum 1.0, 
Amikacinum 1.0), quinolone antibacterials (Gatifloxacinum 
0.4, Acidumpipemidicum 0.8) and antimycotics for systemic 
use (Fluconazolum 0.2). The lowest consumption of 21.53 
(1.37+21.53) or 1.43% of the total in 2010 to 6.61 DDD/1000 
(2.07+3.54) or 0.61% from the total in 2014, with a decrease 
14.92 DDD/1000 by 3.26 times was recorded in that period 
by other two subrgoups: amphenicols (Chloramphenicolum 
3.0) and macrolides, lincosamides and streptogramins (Clari-
thromycinum 0.5, Azithromycinum 0.5, Lincomycinum 1.8). 
In figure 2 consumption rate of enteral forms of anti-
bacterials for systemic use in DDD/1000 during 2010-2014 
is shown. 
As it is seen from figure 2 the average consumption an-
nual rate of antibiotics for oral usage increased from 19.85 
in 2010 to 123.72 DDD/1000 OBD in 2014 or by 6.23 times. 
The highest consumption of 19.85 DDD/1000 or 100% of the 
Fig. 1.  Parenteral consumption forms of antibacterials 
 for systemic use in ddd/1000.
Fig. 2.  Enteral consumption forms of antibacterials  
for systemic use in ddd/1000.
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total in 2010 was registered for antimycotics for systemic use 
and 106.6 DDD/1000 or 86.16% of the total in 2014 for te-
tracyclines. In figure 3 the total (parenteral and enteral forms) 
antibiotic subgroups used rates are demonstrated.
As it can be observed from figure 3 the average aggregated 
annual rate for total antibiotics consumption in the evaluated 
period decreased from 1524 in 2010 to 1206 DDD/1000 in 
2014 or by 20.87%.
The highest yearly consumption for the first 3 subgroups 
during mentioned years remains similar to parenteral use 
(other beta-lactam antibacterials, other antibacterials and 
beta-lactam antibacterials, penicillins) as well as for mean 
(aminoglycoside antibacterials, quinolone antibacterials, 
antimycotics for systemic use)  and lower consumption (am-
phenicols, macrolides, lincosamides and streptogramins).
Nevertheless, though consumption of enteral forms of an-
tibiotics registered a significant increase during the evaluated 
period, the total DDD/1000 consumption wasn’t influenced 
respectively.
As stated in table 1 in the evaluated period the ratio 
between antibiotics DDD/1000 parenteral to enteral forms 
was 75.79:1 in 2010 to 8.75:1 in 2014. The percentage of 
parenteral forms from the total antibiotics DDD/1000 in the 
mentioned period decreased from 98.70% to 89.74%, as well 
as the enteral forms increased from 1.3 to 10.26% of the total. 
Similar data for the entire institution can be found in some 
early publications [10]. Some publications demonstrate that 
in terms of switch therapy, approximately 40-50% of patients 
admitted for intravenous antibiotics can be switched to oral 
antibiotics within 2-3 days [11]. 
From this chart one can see in the evaluated period the 
total consumption of parenteral forms of cephalosporin’s 
decreased from 975 to 598 DDD/1000 or by 38.67%. 
Cephalosporin’s first generation (Cefalexinum and Cefazoli-
num) represents 300.82 DDD/1000 or a share of 30.85% from 
the total in 2010, and 166.77 DDD/1000 or 27.88% from the 
total in 2014 by a decrease of 134.05 DDD/1000 or 44.57% 
during 5 years. The consumption of cephalosporin’s second 
generation (Cefuroximum, Cefaclorum) recorded an incre-
ment from 32.11 DDD/1000 to 163.81 DDD/1000 or by 5.10 
times during the mentioned period. Cephalosporinţ’s third 
generation (Cefotaximum, Ceftazidimum, Ceftriaxonum, 
Cefixim, Cefoperazonum, Cefoperazonum + Sulbactamum) 
demonstrates a considerable decrease of consumption from 
591.72 DDD/1000 in 2010 to 241.74 DDD/1000 in 2014 
or by 2.44 times. Cephalosporins G-IV and carbapemens 
(Meropenemum, Imipenemum+Cilastatinum) recorded a 
consumption lower than 50 DDD/1000.
Comparison of total consumption data of anti-infectives 
for systemic use evaluated in DDD/1000 in 54 intensive 
care units of international hospitals with the similar data of 
Therapeutical intensive care department of EMI is presented 
in figure 2.
As we can see from table 2 the average annual rate for total-
hospital antibiotics utilization period in EMI decreased from 
662.4 in 2010 to 464.1 DDD/1000 in 2014 or by 30%. That 
result was higher by 67.65 DDD/1000 or by 14.58% than the 
medium consumption of 396.45 DDD/1000 registered in case 
of 1256 international hospitals and lower by 112.66 DDD/1000 
or by 36.68% in case of 450 international hospitals where the 
Fig. 3.  The total consumption of antibacterials  
for systemic use in ddd/1000.
Fig. 4.  Total consumption forms of other beta-lactam 
antibacterials for parenteral use in ddd/1000.
Table 1
The ratio between ddd/1000 for parenteral to enteral antibiotic form
Years 2 010 2011 2012 2013 2014
Parenteral 1504.44 1339.95 1576.11 1336.06 1082.36
Enteral 19.85 42.382 68.85 57.239 123.715
The ratio of parenteral to oral 75.79:1 31.62:1 22.89:1 23.34:1 8.75:1
Total 1524.29 1382.33 1644.96 1393.30 1206.08
Percentage from total
Parenteral 98.70 96.93 95.81 95.89 89.74
Enteral 1.30 3.07 4.19 4.11 10.26
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mentioned medium was 634.34 DDD/1000 respectively. Other 
all medium consumption in 1706 international hospitals 
constituting 459.20 DDD/1000 was lower than consumption 
of 464.1 DDD/1000 in EMI in 2014 by 4.90 DDD/1000 or by 
1.06% and lower by 121.1 comparatively to global antibiotics 
consumption of 343 defined daily doses per 1000 patient-days 
or by 20.09% [20]. 
DDD/1000 of antibiotics in Therapeutical intensive care 
department decreased from 1524 in 2010 to 1206 DDD/1000 
in 2014 or by 20.87%, however, it is by 11.77% higher than 
medium consumption of 1064.01 DDD/1000 [(1x1086.5 + 
1x652.0 + 15x1056.0 + 10x1169 + 10x1127 + 8x1013 + 1x1052 
+ 1x462 + 1x683 + 1x982):54] in  intensive care units of 54 
international hospitals with the similar activity.
The value cost of parenteral forms of antibacterials for 
systemic use per DDD/1000 in lei is shown in figure 5.
As we can see from figure 5 the average consumption 
annual rate per DDD/1000 in value indexes (lei) of all paren-
teral antibiotic subgroups recorded a decline from 54782 in 
2010 to 40509 lei in 2014 or by 26.06%. The medium yearly 
consumption for the evaluated period with more than 5000 lei 
per DDD/1000 was registered for other beta-lactam antibacte-
rials (31975.8 lei) and for beta-lactam antibacterials (10146.5 
lei). Other subgroups as other antibacterials, macrolides, 
lincosamides and streptogramins, quinolone antibacterials, 
antimycotics for systemic use registered a medium yearly 
consumption less than 5000 lei per DDD/1000.
The value cost of enteral forms of antibacterials for syste-
mic use per DDD/1000 in lei is presented in figure 6.
Table 2
Surveillance studies of antibiotics use in intensive care units of international hospitals,  
compared with the similar data in therapeutical intensive care department of EMI





Use of antibiotics in DDD/1000 
bed-days over the study 
period
Emergency Medicine Institute 6 years (2010–2014) dispensing records (PDR) Annual
662.4 hospital-wide in 2010            
464.1   hospital-wide   in   2014
Therapeutical intensive care department of  EMI 5 years (2010–2014) (PDR) Annual 1524.29 in 2010 1206.08 in 2014
ICU Tertiary level in Northern India [12] In 2008 (PDR) Annual 1086.5
Neurosurgical ICU of Germany [13] From 2002 to 2005 (PDR) Annual 652.0
40 ICU of Southwestern Germany non university 
regional general hospitals  [14] From 2001 to 2002 (PDR) Annual
 1056.0 (in medical ICU)
 1169.0 (in surgical ICU)
 1127.0 (in mixed ICU)
8 Tertiary intensive care unit in Hungary [15] In 2008 (PDR) Annual 1013.0
ICU of Military Medical Academy hospital of 
Bulgaria [16] In 2011 (PDR) Annual 1052.0
ICU of 1 university hospital in Switzerland 
[17x24Loeffler, JM, Garbino, J, Lew, D, Harbarth, S, 
and Rohner, P. Antibiotic consumption, bacterial 
resistance and their correlation in a Swiss uni-
versity hospital and its adult intensive care units. 
Scand J Infect Dis. 2003; 35: 843–850
CrossRef | PubMed | Scopus (47) See all  
References24]
5 years (1996–2000) (PDR) Annual
462.0 (in surgical ICU)  
683.0 (in medical ICU)
400.0 (in the entire hospital)
ICU of 1 university hospital in Greece  
(personal unpublished data) [18] 5 years (1998–2002) (PDR) Annual 982.0 (in mixed ICU) 
The global antibiotics consumption [19] From 2006 to 2008 varied little (PDR) Annual 343.0 
Fig. 5.  Value cost of parenteral forms of antibacterials  
for systemic use per ddd/1000 in lei.
Fig. 6.  Value cost of enteral forms of antibacterials  
for systemic use per ddd/1000 in lei.
From figure 6 it can be found that the average consumption 
annual rate in value indexes of all antibiotic subgroups records 
an increase from 167 in 2010 to 216 lei per DDD/1000 in 2014 
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or by 29.34%. All other subgroups recorded consumption per 
DDD/1000 less than 100 lei.  Total value cost of antibacterials 
for systemic use per DDD/1000 in lei is shown in figure 7.
In this chart the presented data demonstrate that the 
average consumption annual rate in value indexes of total 
antibiotics record a decline from 54948 in 2010 to 40754 
lei per DDD/1000 in 2014 or by 25.84%. The highest yearly 
cost of DDD/1000 of the total antibacterials for systemic use 
represents other beta-lactam antibacterials and beta-lactam 
antibacterials. Introduction of coordinated cost control pro-
gram and prescribed protocols established by consensus as 
guidelines for a rational policy in antibiotics therapy in some 
institutions result in decreasing of value cost during 2 years 
by more than 40% [21, 22].
Total value cost of other beta-lactam antibacterials for 
parenteral use of DDD/1000 in lei is presented in figure 8.
Figure 8 shows that the cost of DDD/1000 in value indexes 
(lei) of antibiotic subgroups for parenteral use recorded a de-
cline from 35144 in 2010 to 29271 lei in 2014 or by 16.72%. As 
an exception from the decline was 2011 year with the higher 
consumption of 44122 lei per DDD/1000. An increment in 
cost per DDD/1000 was recorded by the second generation 
of cephalosporin’s from 859.24 in 2010 to 5525.00 lei in 2014 
or by 6.43 times. Third cephalosporin’s generation slightly 
increased cost per DDD/1000 from 13884.1 in 2010 to 14948 
lei in 2014 or by 7.66%. A decrement in the evaluated period 
was recorded by the first generation of cephalosporins from 
3113.05 lei per DDD/1000 to 1605.5 or by 48.43% and car-
bapenems from 8508.83 lei per DDD/1000 to 7192.70 or by 
18.29%.
To determine the cost of one medium DDD of antibac-
terials for systemic use separately for parenteral and enteral 
forms, the cost sum of DDD/1000 per DDD/1000 was divided 
respectively. The cost of one medium DDD of antibiotics in lei 
for parenteral and enteral forms and total is shown in table 3.
As we can see from table 3 in the evaluated period the cost 
of one medium DDD recorded a slow increase from 36.41 lei 
in 2010 to 37.43 lei in 2014 or by 2.80% for parenteral forms, a 
decrease from 8.41 to 1.75 lei or by 4.80 times for enteral forms 
and from 36.05 to 33.77 lei or by 6.33% for one total DDD. In 
chronological way for the evaluated years the ratio between 
the cost of one medium DDD of parenteral to enteral forms 
was respectively 4.32:1; 9.78:1; 5.97:1; 4.81:1 and 21.38:1. 
Treatment patterns, antibiotics stewardship activity, 
potential opportunities for early switch from intravenous to 
oral formulations [23] and measures necessary for preventing 
and strengthening antimicrobials resistance and nosocomial 
infections will lead to potential cost savings per every eligible 
patient [24, 25, 26]. 
Fig. 7. Total value cost of antibacterial  
for systemic use per ddd/1000 in lei. Fig. 8. Total value cost of other beta-lactam antibacterials  for parenteral use of ddd/1000 in lei.
Table 3
cost of 1(one) ddd of antibiotics in lei for parenteral and enteral forms and total
Year/ cost (in lei) 2010 2011 2012 2013 2014
Parenteral cost in lei per DDD/1000 54781.50 83156.00 54644.40 39904.00 40509.00
Enteral cost in lei per DDD/1000 166.88 255.99 399.13 355.18 216.23
Total cost in lei  per DDD/1000 54948.38 83411.99 55043.53 40259.18 40725.23
Parenteral DDD/1000 1504.45 1339.95 1576.11 1336.06 1082.36
Enteral DDD/1000 19.85 42.382 68.85 57.239 123.715
Total DDD/1000 1524.29 1383.83 1644.95 1394.77 1206.07
Cost  in lei per 1(one) DDD 36.05 60.43 33.61 28.89 33.77
Parenteral cost in lei per 1(one) DDD 36.41 62.06 34.67 29.87 37.43
Enteral cost in lei per 1(one) DDD 8.41 6.04 5.80 6.2 1.75
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Conclusions
1. The DDD/1000 of antibiotics in therapeutical inten-
sive care department decreased from 1524 in 2010 to 1206 
DDD/1000 in 2014 or by 20.87%, however, it was by 11.77% 
higher than medium consumption of 1052.25 DDD/1000 in 
intensive care units of 54 international hospitals. The con-
sumption of parenteral forms constituting 1504.44 or 98.70% 
from the total in 2010 and 1082.36 DDD/1000 or 89.74% from 
the total in 2014 had an overall decrease of 29.06%. For enteral 
forms the stated data were 19.85 or 1.30% from the total in 
2010 to 123.72 DDD/1000 or 10.25% from the total in 2014 
or an increase by 6.23 times respectively.
2. The value of 54948 lei per DDD/1000 OBD in 2010 
recorded a decline to 40754 lei in 2014 or by 25.84%. The cost 
of one medium DDD from 36.05 lei in 2010 decreased to 33.77 
lei in 2014 or by 6.33%. International experience demonstrates 
that introduction of coordinated cost control program and 
prescribed protocols can lead to a decrease of anti-microbials 
treatment cost during 2 years by more than 40%.
3. 36 antimicrobial remedies with different dosage of ad-
ministration with: enteral forms – 7 names, parenteral forms 
– 29 names and with both forms – 3 names, that represent 23 
active antimicrobial substances in the period from 2010-2014 
were evaluated. 
4. Besides the drugs consumption evaluation in DDD 
that permits to improve rational use of medical remedies 
in hospitals of the Republic of Moldova, daily practices in 
antimicrobial treatment of potential opportunities for early 
switch from intravenous to oral formulations, coordinated 
cost control program and prescribed protocols established as 
guidelines for a rational policy in antibiotics therapy, and the 
last but not the least the measures for preventing and stren-
gthening antimicrobials resistance and nosocomial infections 
as well will lead to growing treatment quality of hospitalized 
patients and potentially saving institutional budgets. 
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